IL-34 Upregulated Th17 Production through Increased IL-6 Expression by Rheumatoid Fibroblast-Like Synoviocytes

Table 1

Baseline clinical characteristics and medication of RA patients ( ± SEM or n%).

	Baseline value
Age, year	50.29 ± 0.93
Male/female	40/128
Disease duration, years	9.62 ± 2.23
DAS28	4.41 ± 1.39
ESR, mm/h	55.69 ± 3.68
CRP, μg/ml	33.84 ± 3.50
RF, IU/ml	79.01 ± 7.39
Anti-CCP Ab, U/ml	173.80 ± 18.35
Current NSAID users	4 (2.38)
Current DMARD users	21 (12.50)
Current steroid users	2 (11.90)
Two-type drug users	67 (39.88)
Three-type drug users	15 (8.93)
No systemic therapy patients	59 (35.11)

ESR: erythrocyte sedimentation rate; CRP: C-reactive protein; DAS: disease activity score; RF: rheumatoid factor; CCP: cyclic citrullinated peptide; NSAIDs: nonsteroidal anti-inflammatory drugs; DMARDs: disease-modifying antirheumatic drugs.